Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Gmbh

Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Karl Thomae Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Boehringer Ingelheim Kg

Boehringer Ingelheim Pharma Kg

Karl Thomae Gesellschaft MIT Beschrankter Haftung

Roland Maier

Michael Mark

Eberhard Woitun

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Uwe Lechner

Bernd Wetzel

Hanns Goeth

Wolfgang Reuter

Mohammad Tadayyon

Rudolf Hurnaus

Ralf Lotz

Ralf R H Lotz

Gerhard Hallermayer

Bernhard Eisele

Ralph-Michael Budzinski

Peter Muller

Peter Baruch Mueller

Gebhard Adelgoss

Gebhard Schilcher

Rolf G Werner

Bernard Eisele

Norbert Hauel

Wolfgang Eberlein

Leo Thomas

Gunter Trummlitz

Helmut Ensinger

Iris Kauffmann-Hefner

Thomas Weiser

Wolf-Dietrich Bechtel

Rainer Palluk

Michael Brenner

Marion Wienrich

Uwe Pschorn

Angelo Sagrada

Rudolph Hurnaus

Raffaele Cesana

Eberhard Waitun

Wolfgang Rueter

Hans Goeth

Wolfang Reuter

Ralf Richard Lotz

Ralf Richard Hermann Lotz

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

Xanthine derivates, their preparation and their use in pharmaceutical compositions

Disclosed are substituted xanthines of general formula wherein Rto Rare defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The invention relates to new purine derivatives of general formula wherein Rto Rare defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

Purine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Compounds of formula (I) wherein Ris a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and Rto Rare defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.

Xanthine derivatives, their preparation and their use in pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein Rto Rare defined as in claimsto, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Growing community of inventors

Biberach, Germany

Roland Maier